The current financial score of Sutro Biopharma Inc is 5.34. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 9.10M, representing a year-over-year decrease of 6.14%, while its net profit experienced a year-over-year decrease of 44.62%.
The current valuation score of Sutro Biopharma Inc is 8.51. Its current P/E ratio is -0.60, which is -70.28% below the recent high of -0.18 and -496.57% above the recent low of -3.60.
The current earnings forecast score of Sutro Biopharma Inc is 8.29. The average price target is 47.23, with a high of 61.00 and a low of 10.00.
The current price momentum score of Sutro Biopharma Inc is 5.36. Currently, the stock price is trading between the resistance level at 11.71 and the support level at 8.02, making it suitable for range-bound swing trading.
The current institutional shareholding score of Sutro Biopharma Inc is 3.00. The latest institutional shareholding proportion is 45.76%, representing a quarter-over-quarter decrease of 31.45%.
The current risk assessment score of Sutro Biopharma Inc is 3.93. The company's beta value is 1.57. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.